Blumberg B S, Millman I, Venkateswaran P S, Thyagarajan S P
Fox Chase Cancer Center, Philadelphia, PA.
Vaccine. 1990 Mar;8 Suppl:S86-92. doi: 10.1016/0264-410x(90)90225-b.
A viricide capable of eliminating hepatitis B virus (HBV) from chronic carriers should, theoretically, decrease the risk of primary hepatocellular carcinoma. Extracts of Phyllanthus amarus have been shown to inhibit the DNA polymerase of HBV and woodchuck hepatitis virus (WHV) in vitro. Three of four recently infected WHV carriers treated i.p. with P. amarus extract lost WHV, animals infected for greater than or equal to 3 months showed a decrease in virus levels. Preliminary results in human carriers treated orally with P. amarus for 1 month indicated that approximately 60% of the carriers lost HBV during the observation period.
从理论上讲，一种能够清除慢性携带者体内乙肝病毒（HBV）的杀病毒剂应可降低原发性肝细胞癌的风险。苦味叶下珠提取物已在体外显示出对乙肝病毒和土拨鼠肝炎病毒（WHV）的DNA聚合酶具有抑制作用。四只近期感染土拨鼠肝炎病毒的携带者中有三只经腹腔注射苦味叶下珠提取物后病毒消失，感染时间大于或等于3个月的动物体内病毒水平有所下降。对人类携带者口服苦味叶下珠进行为期1个月的初步治疗结果表明，在观察期内约60%的携带者体内乙肝病毒消失。
